Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigatio ...
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders should be happy to see the share price up 11% in the ...
Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...
Fmr LLC cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 10.9% in the third quarter, ...
Charles Schwab Investment Management Inc. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – ...
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
Arrowhead Pharmaceuticals, Inc. ( (ARWR) ) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that ... therapeutics leverage this natural pathway of gene silencing. This news release contains forward-looking statements within the meaning of ...
About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals ... under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of ...
GlobalData on MSN14d
Arrowhead and Sarepta link for rare genetic disease treatmentsArrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback